Baohui Han

472 total citations
8 papers, 43 citations indexed

About

Baohui Han is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Baohui Han has authored 8 papers receiving a total of 43 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Baohui Han's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Baohui Han is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Baohui Han collaborates with scholars based in China and United States. Baohui Han's co-authors include Bo Zhang, Hua Zhong, Yun Fan, Xicheng Wang, Xiaoli Zhu, Liang Han, Dongqing Lv, Lin Wu, Shaozhang Zhou and Yan Yu and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and JAMA Oncology.

In The Last Decade

Baohui Han

8 papers receiving 43 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Baohui Han China	5	31	26	7	6	6	8	43
Alain Gratet France	3	23 0.7×	16 0.6×	5 0.7×	11 1.8×	9 1.5×	7	43
Jade M. van Berge Henegouwen Netherlands	4	27 0.9×	18 0.7×	5 0.7×	6 1.0×	10 1.7×	12	40
Julie S. Deutsch United States	5	26 0.8×	21 0.8×	8 1.1×	12 2.0×	4 0.7×	9	43
Spartak Valev Bulgaria	3	47 1.5×	20 0.8×	9 1.3×	9 1.5×	10 1.7×	6	69
R. Coleman United States	4	27 0.9×	20 0.8×	3 0.4×	5 0.8×	9 1.5×	18	49
Alexander H. Song United States	2	22 0.7×	16 0.6×	6 0.9×	17 2.8×	13 2.2×	5	44
Tomonori Hirano Japan	3	10 0.3×	23 0.9×	4 0.6×	6 1.0×	4 0.7×	6	36
Karina Vianna Brazil	4	36 1.2×	19 0.7×	7 1.0×	7 1.2×	4 0.7×	6	40
Sarah Warren United States	3	32 1.0×	10 0.4×	19 2.7×	5 0.8×	8 1.3×	6	43
Ewa Szutowicz-Zielińska Poland	3	23 0.7×	17 0.7×	3 0.4×	9 1.5×	3 0.5×	5	39

Countries citing papers authored by Baohui Han

Since Specialization

Citations

This map shows the geographic impact of Baohui Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baohui Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baohui Han more than expected).

Fields of papers citing papers by Baohui Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baohui Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baohui Han. The network helps show where Baohui Han may publish in the future.

Co-authorship network of co-authors of Baohui Han

This figure shows the co-authorship network connecting the top 25 collaborators of Baohui Han. A scholar is included among the top collaborators of Baohui Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baohui Han. Baohui Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2023). Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.. Journal of Clinical Oncology. 41(16_suppl). 9003–9003. 4 indexed citations

Li, Yujing, Fangfei Qian, Yanwei Zhang, et al.. (2023). Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance. Frontiers in Immunology. 14. 2 indexed citations

Zhang, Bo, Hua Zhong, & Baohui Han. (2023). Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer—Is a New Era Coming?. JAMA Oncology. 9(3). 301–301. 11 indexed citations

Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2022). Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations. Journal of Clinical Oncology. 40(36_suppl). 362936–362936. 5 indexed citations

Han, Baohui, Trevor Feinstein, Yuankai Shi, et al.. (2022). Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone.. Journal of Clinical Oncology. 40(16_suppl). 9090–9090. 3 indexed citations

Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2022). Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.. Journal of Clinical Oncology. 40(16_suppl). 9028–9028. 8 indexed citations

Han, Baohui, Bo Yan, Tianqing Chu, et al.. (2022). Phase Ib/IIa study evaluating the safety and clinical activity of osimeritinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients (AUTOMAN).. Journal of Clinical Oncology. 40(16_suppl). e21140–e21140. 4 indexed citations

Han, Baohui, et al.. (2013). Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. Asian Pacific Journal of Tropical Medicine. 6(11). 912–915. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact